Symbols

GOSS

Gossamer Bio·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GOSS

Gossamer Bio, Inc.

A clinical-stage biopharmaceutical company that developing therapeutics in the disease areas of immunology, inflammation and oncology

Industry

Biological Technology

Established Date

10/26/2015

Listing Date

02/08/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

144

Fiscal Year Ends

12-31

Website

www.gossamerbio.com

Security Type

Common stock

Office address

3013 Science Park Road, San Diego, California 92121

Business

Introduction

Gossamer Bio, Inc., was incorporated under Delaware law on October 26, 2015 under the name FSG, Bio, Inc., and changed its name to Gossamer Bio, Inc., Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, in 2017, Focus on the development and commercialization of ceratinib for the treatment of pulmonary hypertension or PAH. The company's goal is to become an industry leader and improve the lives of patients with pulmonary hypertension, or PH. To achieve this goal, the company brings together a group of experienced and skilled industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. The company intends to maintain a corporate culture of scientific rigor and inclusiveness, with employees striving to bring better treatment options to patients.

Company Financials

EPS

GOSS has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.2, missing expectations. The chart below visualizes how GOSS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GOSS has released its 2025 Q3 earnings report, with revenue of 13.29M, reflecting a YoY change of 40.23%, and net profit of -48.22M, showing a YoY change of -56.55%. The Sankey diagram below clearly presents GOSS's revenue sources and cost distribution.